Quantcast

Latest oral mucositis Stories

2010-06-15 07:30:00

DALLAS and NEW YORK, June 15 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC.

2010-04-21 07:30:00

DALLAS and NEW YORK, April 21 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC.

2010-04-15 07:30:00

DALLAS and NEW YORK, April 15 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it is collaborating with leading expert in oral mucositis ("OM"), Stephen T.

2010-04-13 07:30:00

DALLAS and NEW YORK, April 13 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced that it has completed its first commercial scale production run of MuGard in North America at Accupac, Inc. manufacturing facilities outside Philadelphia.

2010-03-25 07:30:00

DALLAS, March 25 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC.

2009-12-15 08:00:00

DALLAS, Dec. 15 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today announced the appointment of Frank Jacobucci to the position of Vice President, Sales and Marketing. Mr.

2009-12-03 11:48:00

DALLAS, Dec. 3 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.

2009-11-11 08:00:00

DALLAS, Nov. 11 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its North American commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.

2009-10-15 07:00:00

DALLAS, Oct. 15 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.

2009-10-06 07:00:00

DALLAS, Oct. 6 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC.